The CCKB antagonist PD-134,308 facilitates rewarding effects of endogenous enkephalins but does not induce place preference in rats

Psychopharmacology

Volumn 123, Issue 2, 1996, Pages 119-126

  Valverde, Olga ^a   Fournié Zaluski, Marie Claude ^a   Roques, Bernard P ^a   Maldonado, Rafael ^a  

^a INSERM   (France)

Author keywords

CCKB antagonist; Conditioned place preference; Endogenous enkephalins; PD 134,308; RB 101; Reward

Indexed keywords

4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; ENKEPHALIN; ENZYME INHIBITOR; MORPHINE; N [3 [(2 AMINO 4 METHYLTHIO)BUTYLDITHIO] 2 BENZYLPROPIONYL]PHENYLALANINE BENZYL ESTER; CHOLECYSTOKININ RECEPTOR; DRUG DERIVATIVE; HORMONE ANTAGONIST; INDOLE DERIVATIVE; MEGLUMINE;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONDITIONING; CONTROLLED STUDY; FACILITATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOTIVATION; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; RAT; REWARD; SUBCUTANEOUS DRUG ADMINISTRATION; TAIL FLICK TEST; ANIMAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; PAIN ASSESSMENT; WISTAR RAT;

ANIMALS; CONDITIONING (PSYCHOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; ENKEPHALINS; HORMONE ANTAGONISTS; INDOLES; MALE; MEGLUMINE; MORPHINE; PAIN MEASUREMENT; RATS; RATS, WISTAR; RECEPTORS, CHOLECYSTOKININ;

EID: 0029665263     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02246168     Document Type: Article

References (51)

1. Agmo A, Gómez M, Irazabal Y (1994) Enkephalinase inhibition facilitates sexual behavior in the male rat but does not produce conditioned place preference. Pharmacol Biochem Behav 47: 771-778
2. Altar CA, Boyar WC, Oei E, Wood PL (1988) Cholecystokinin attenuates basal and drug-induced increases in limbic and striatal dopamine release. Brain Res 460:76-82
3. Amalric M, Cline EJ, Martínez JL Jr, Bloom FE, Koob GF (1987) Rewarding properties of β-endorphin as measured by conditioned place preference. Psychopharmacology 91:14-19
4. 1 dopamine receptor stimulation. Eur J Pharmacol 216:157-166
5. Bals-Kubik R, Ableitner A, Herz A, Shippenberg TS (1993) Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats. J Pharmacol Exp Ther 264:489-495
6. Bechara A, Van der Kooy (1985) Opposite motivational effects of endogenous opioids in brain and periphery. Nature 314: 533-534
7. Bozarth MA, Wise RA (1984) Anatomically distinct opiate receptor fields mediate reward and physical dependence. Science 224: 516-517
8. Broekkamp CL, Phillips AG, Cools AR (1979) Stimulant effects of enkephalin microinjections into the dopaminergic A10 area. Nature 278: 560-562
9. Caine SB, Lintz, R, Koob GF (1993) Intravenous self-administration techniques in animals. In: Sahgal A (ed) Behavioral neuroscience: a practical approach. Oxford University Press. Oxford, pp 54-62
10. Crawley JN (1992) Subtype-selective cholecystokinin receptor antagonist block cholecystokinin modulation of dopamine-mediated behaviors in the rat mesolimbic pathways. J Neurosci 12:3380-3391
11. Crawley JN, Hommer DW, Skirboll LK (1985) Topographical analysis of nucleus accumbens sites at which cholecystokinin potentiates dopamine-induced hyperlocomotion. Brain Res 355:320-330
12. D'Amour FE, Smith DL, (1941) A method for determining loss of pain sensation. J Pharmacol Exp Ther 72:74-79
13. Daugé V, Steimes P, Derrien M, Beau N, Roques BP, Feger J (1989) CCK-8 effects on motivational and emotional states of rat involve CCK-A receptors of the postero-median part of the nucleus accumbens. Pharmacol Biochem Behav 34: 157-163
14. Daugé V, Kalivas PW, Duffy T, Roques BP (1992) Effects of inhibiting enkephalin catabolism in VTA on motor activity and extracellular dopamine. Brain Res 599:209-214
15. B antagonists in mice: antagonism by naltrindole. Br J Pharmacol 111:956-960
16. Fans P, Komisaruk BR, Watkins LR, Mayer D (1983) Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science 219:310-312
17. File SE (1986) Aversive and appetitive properties of anxiogenic and anxiolytic agents. Behav Brain Res 21:189-194
18. Fournié-Zaluski MC, Coric P, Turcaud S, Lucas E, Noble F, Maldonado R, Roques BP (1992) Mixed-inhibitor prodrug as a new approach towards systemically active inhibitors of enkephalin degrading enzymes. J Med Chem 35:2473-2481
19. Funada M, Suzuki T, Narita M, Misawa M, Nagase H (1993) Blockade of morphine reward through the activation of k-opioid receptors in mice. Neuropharmacology 32:1315-1323
20. Gall C, Lauterborn J, Burks D, Serogy K (1987) Co-localization of enkephalins and cholecystokinin in discrete areas of rat brain. Brain Res 403:403-408
21. Glimcher PW, Giavino AA, Margolin DH, Hoebel BG (1984) Endogenous opiate reward induced by an enkephalinase inhibitor, thiorphan, injected into the ventral midbrain. Behav Neurosci 98:262-268
22. Hand TH, Franklin KBJ (1985) 6-OHDA lesions of the ventral tegmental area block morphine-induced but not amphetamine-induced facilitation of self-stimulation. Brain Res 328:233-241
23. B receptor antagonist L-365,260 elicits antidepressant-type effects in the forced-swim test in mice. Eur J Pharmacol 261:257-263
24. A receptor antagonist devazepide. Eur J Pharmacol 197:229-230
25. B receptor antagonists. Brain Res 572:208-215
26. Hökfelt T, Rehfeld JF, Skirboll LR, Ivemark B, Goldstein M, Markey K (1980) Evidence for coexistence of dopamine and CCK in meso-limbic neurones. Nature 285:476-478
27. Hughes J, Boden P, Costall B, Domeney A, Kelly E, Horwell DC, Hunter JC, Pinnock RD, Woodruff GN (1990) Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc Natl Acad Sci USA 87:6728-6732
28. Koob GF, Goeders NE (1989) Neuroanatomical substrates of drug self-administration. In: Liebman JM, Cooper SJ (eds) The neuropharmacological basis of reward. Oxford University Press, Oxford, pp 214-263
29. Ladurelle N, Keller G, Roques BP, Daugé V (1993) Effects of CCK8 and of the CCK B-selective agonist BC264 on extracellular dopamine content in the anterior and posterior nucleus accumbens: a microdialysis study in freely moving rats. Brain Res 628:254-262
30. Maldonado R, Derrien M, Noble F, Roques BP (1993) Association of a peptidase inhibitor and a CCK-B antagonist strongly potentiates antinociception mediated by endogenous enkephalins. Neuroreport 7:947-950
31. Maldonado R, Valverde O, Turcaud S, Fournié-Zaluski MC and Roques BP (1994) Antinociceptive response induced by mixed inhibitors of enkephalin catabolism in peripheral inflammation. Pain 58:77-83
32. Mucha RF, Herz A (1985) Motivational properties of kappa and mu opioid receptor agonists studied with place and taste preference conditioning. Psychopharmacology 86:274-280
33. Mucha RF, Van der Kooy D, O'Shaughnessy M, Bucenieks P (1982) Drug reinforcement studied by use of place conditioning in rat. Brain Res 243:91-105
34. Noble F, Soleilhac JM, Soroca-Lucas E, Turcaud S, Fournié-Zaluski MC, Roques BP (1992a) Inhibition of the enkephalin catabolizing enzymes by the first systemically active mixed inhibitor prodrug RB 101 induces potent analgesic responses in mice and rats. J Pharmacol Exp Ther 261:181-187
35. Noble K, Turcaud S, Fournié-Zaluski MC, Roques BP (1992b) Repeated systemic administration of the mixed of enkephalin-degrading enzymes, RB 101, does not induce either antinociceptive tolerance or cross-tolerance with morphine. Eur J Pharmacol 223:83-89
36. Noble F, Coric P, Furnié-Zaluski MC, Roques BP (1992c) Lack of physical dependence in mice after repeated systemic administration of the mixed inhibitor prodrug of enkephalin-degrading enzymes, RB 101. Eur J Pharmacol 223:94-96
37. Noble F, Fournié-Zaluski MC, Roques BP (1993) Unlike morphine the endogenous enkephalins protected by RB 101 are unable to establish a conditioned place preference in mice. Eur J Pharmacol 230:139-149
38. Pettit HO, Batsell WR Jr, Mueller K (1989) Triazolam attenuates amphetamine but not morphine conditioned place preferences. Psychopharmacology 98:483-486
39. 5-enkephalin, and dynorphin A (1 8) like materials in the spinal cord and dorsal root ganglia of adults rats. Effects of dorsal rhizotomy and neonatal capsaicin. J Neurochem 55:1122-1130
40. Roques BP, Daugé V, Gaeel G, Fournié-Zaluski MC (1986) Selective agonists and antagonists of delta opioid receptors and inhibitors of enkephalins metabolism. Potential use in treatment of mental illness. Biol Psychiatry 7:287-289
41. Roques BP, Noble F, Daugé V, Fournié-Zaluski MC, Beaumont A (1993) Neutral endopeptidase 24.11: structure, inhibition and experimental and clinical pharmacology. Pharmacol Rev 45: 87-146
42. Ruiz-Gayo M, Baamonde A, Turcaud S, Fournié-Zaluski MC, Roques BP (1992a) In vivo occupation of mouse brain opioid receptors by endogenous enkephalins: blockade of enkephalin degrading enzymes by RB 101 inhibits [3H]diprenorphine binding. Brain Res 571:306-312
43. 3H]pBC 264: evidence for a physiological regulation of CCKergic system by endogenous enkephalins. J Neurochem 59:1805-1811
44. 1-dopamine receptors in the motivational properties of μ- and k-opioid agonist. Brain Res 436: 169-172
45. Shippenberg TS, Bals-Kubik R, Herz A (1993) Examination of the neurochemical substrates mediating the motivational effects of opioids: role of the mesolimbic dopamine system and D-1 vs D-2 dopamine receptors. J Pharmacol Exp Ther 265:53-59
46. B receptors in the modulation of endogenous enkephalins antidepressant-like effects. Psychopharmacology 120:400-408
47. Suzuki T, Yoshiike M, Funada M, Mizoguchi H, Kamei J, Misawa M (1993) Effect of cyclosporine A on the morphine-induced place preference Neurosci Lett 160:159-162
48. Swerdlow NR, Gilbert D, Koob GF (1989) Conditioned drug effects on spatial preference. Critical evaluation. In: Boulton AA, Baker GB, Greenshaw AJ Neuromethods (Psychopharmacology, vol. 13). Humana Press, New York, pp 399-446
49. Valverde O, Maldonado R, Fournié-Zaluski MC, Roques BP (1994) Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins. J Pharmacol Exp Ther 270:77-88
50. Wise RA (1980) Action of drugs of abuse on brain reward system. Pharmacol Biochem Behav 13:213-223
51. Zimmermann M (1983) Guest editorial. Pain 16:109-110